Evidence map›Paper›PMID 30536805›Full record

ArticleJournal of cellular physiology2019

Attenuation of aquaporin-3 and epidermal growth factor receptor expression and activation in systemic sclerosis dermal fibroblasts.

Elham Farhadi, Mahdi Mahmoudi, Farzaneh Rahmani, Bahman Yousefi, Abdolfattah Sarafnejad, Hoda Kavosi, Elham Karimizadeh, Ahmadreza Jamshidi, Farhad Gharibdoost

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Aquaporins in Skin.Advances in experimental medicine and biology · 2023
    Article
  4. Article
  5. Review
  6. Aquaporin-3 in the epidermis: more than skin deep.American journal of physiology. Cell physiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Elham FarhadiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mahdi MahmoudiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8164-8831
Farzaneh RahmaniStudent's Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Bahman YousefiDepartment of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
Abdolfattah SarafnejadDepartment of Immunology, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences, Tehran, Iran.
Hoda KavosiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Elham KarimizadehRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ahmadreza JamshidiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Farhad GharibdoostRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRSemnan University of Medical Sciences · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesImpaired wound healing and skin dehydration are the mainstay of systemic sclerosis (SSc) cutaneous manifestations. Aquaporin-3 (AQP3) has a pivotal role in skin hydration and wound healing. Epidermal growth factor receptor (EGFR) activation is impaired in SSc fibroblasts. It is unclear whether AQP3 downregulation or epidermal growth factor (EGF) signaling are the primary points of dysregulation in SSc patients.

methodsSkin punch biopsies were obtained from 10 SSc patients and 10 healthy subjects. The mRNA and/or protein expression levels of AQP3, EGFR/p-EGFR, matrix metalloproteinase-1/2/9 (MMP-1/2/9), and tissue inhibitors of metalloproteinase-1 (TIMP1) at baseline and after EGF and transforming growth factor-β1 (TGF-β1) treatment was evaluated in extracted fibroblasts using real-time polymerase chain reaction and western blot analysis.

resultsSSc fibroblasts expressed lower AQP3 and EGFR, compared with normal fibroblasts. Normal fibroblasts increased AQP3 expression in response to EGF whereas AQP3 expression had no change in EGF-treated-SSc fibroblasts. Likewise, EGFR was activated in response to EGF in the normal group but not SSc group. Baseline expression of MMP-1/2/9 and TIMP1 was not different between SSc and controls. EGF treatment did not result in alteration of any MMPs expression in either of the groups. Combination treatment resulted in a significant upregulation of MMP-1 in normal fibroblasts compared with SSc fibroblasts, while in SSc fibroblasts MMP-9 expression was upregulated in response to treatment with TGF-β1 only.

conclusionDownregulation of AQP3 expression in SSc fibroblasts may be related to reduced EGFR expression and activation. TGF-β1 (alone or in combination with EGF) only can upregulate AQP3 expression in SSc fibroblasts so, TGF-β1 affect MMP-1 and MMP-9 just in SSc fibroblasts.

Indexed as

AdultAquaporin 3Cells, CulturedEpidermal Growth FactorErbB ReceptorsFemaleFibroblastsHumansMaleMiddle AgedScleroderma, SystemicSignal TransductionAQP3 protein, humanAquaporin 3EGFR protein, humanEpidermal Growth FactorErbB Receptorsaquaporin-3epidermal growth factor receptorsclerodermaskin fibroblast

Identifiers

PMID30536805
PMCPMC13483328
OpenAlexW2903873523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.